Interlukin‐5 (IL‐5) plays a crucial role in the pathogenesis of eosinophilic granulomatosis with polyangiitis (EGPA) by promoting eosinophil differentiation, activation, and survival. We present here a typical case of EGPA in which treatment with IL‐5 pathway inhibitors is prescribed, showing to be beneficial for the patient. We discuss available evidence proving the association between IL‐5 and clinical activity in EGPA and review the clinical efficacy and safety of currently approved IL‐5 pathway inhibitors (i.e. mepolizumab and benralizumab) that improve disease control, reduce relapse rates, and have significant glucocorticoid‐sparing effects in EGPA by reducing eosinophilic inflammation.